FREMONT, Calif., June 16, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTCBB: WGBS), a leading developer of state-of-the-art genomic analysis systems, today announced that it will present an overview of the company at the annual OneMedForum New York 2011 sponsored by OneMedPlace for emerging healthcare and life science companies June 23-24, 2011.
The presentation will occur at The Roosevelt Hotel in New York on Thursday, June 23rd, 2011 at 11:45 a.m. Eastern time. It will be Webcast live, may be accessed at www.wafergen.com, and will be available for 90 days. For additional information, go to www.onemedplace.com/forum/
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries. The company recently closed a $30.6 billion financing of equity and debt with three leading institutional life science investors, Great Point Partners, LLC, Deerfield Management and Merlin Nexus, and certain members of the Board and management. WaferGen will use the net proceeds from this financing to expand the commercialization capabilities of the company to market its breakthrough SmartChip Real-Time PCR system to penetrate the high-growth genomic analysis segments of the $10 billion genomics market.
As the next-generation Real-Time PCR platform for the discovery and validation of gene expression patterns (biomarkers) on a single platform, the SmartChip System is ideal for researchers seeking to confirm discoveries made with the growing use of next-generation sequencing. The platform is designed to provide high-throughput capabilities that can extend research across large panels of genes, and hundreds of samples, at a very reasonable cost. WaferGen and early SmartChip customers have presented recent data results at various scientific conferences including: the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 by the Oncology Division at Stanford University School of Medicine; the 7th Annual CHI microRNA in Human Disease and Development; a technical seminar at Harvard Institutes of Medicine, Harvard Medical School; and 5th International qPCR Symposium and Industrial Exhibition and Applications Workshop.
In addition, the company offers an innovative fee-based service for gene-expression profiling using the SmartChip System. For additional information, please see http://www.wafergen.com.
Forward Looking Statements
This press release contains certain “forward-looking statements”. Such statements include statements relating to the future use of proceeds received from the company’s recent financing, statements relating to the expected throughput levels of the SmartChip Real-Time PCR System, and other statements relating to future events are not historical facts, including statements which may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company may need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company’s proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K for the year ended December 31, 2010 and the company’s most recent Quarterly Report on Form 10-Q for the period ended March 31, 2011. Security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
WaferGen Contacts
510-651-4450
Don Huffman, CFO
don.huffman@wafergen.com
Media: Joyce Strand
joyce.strand@wafergen.com
Investors: Tim Ryan
tryan@shorehamgroupllc.com
212-242-7777
SOURCE WaferGen Biosystems, Inc.
